Anúncio
relacionado a: OppenheimerIf you have a $500,000+ portfolio, download "13 Retirement Investment Blunders to Avoid". Download "13 Retirement Investment Blunders to Avoid" from Fisher Investments.
- Contact Us
Do you have further questions?
Contact us to learn more.
- Retirement Income Guide
Discover How To Make Your
Portfolio Work For You!
- 13 Retirement Blunders
Retire at ease, avoid these errors.
Blunder #9: Buying Annuities.
- 401(k) and IRA Tips
Learn the differences.
Is it time to rollover your 401(k)?
- Investments in Retirement
Find out some of the best ways
to invest to reach your goals.
- 15-Minute Retirement Plan
Download Our Free Retirement Guide.
Covers Key Planning Factors & More.
- Contact Us
Resultado da Busca
Há 13 horas · Oppenheimer is changing the firm’s estimates for Microsoft’s Azure revenue and CAPX by lowering Azure revenue, and putting CapEx spending around $2B below the Street the next few years after ...
Há 13 horas · El viernes, Oppenheimer ha aumentado el precio objetivo para las acciones de Kymera Therapeutics (NASDAQ:KYMR) a 56 dólares, desde los 52 dólares anteriores, mientras que mantiene una calificación de Outperform en la acción. El ajuste se produce tras una reciente ronda de financiación y refleja ...
Há 13 horas · Las principales ideas bursátiles de Oppenheimer de cara a octubre. Con las acciones en camino a otro mes positivo, Oppenheimer destaca varios nombres que cree que están preparados para ganar ...
Há 2 horas · -- Uber Technologies has an average rating of buy and price targets ranging from $66 to $102, according to analysts polled by Capital IQ. Price: 76.64, Change: -0.05, Percent Change: -0.07 ...
Há 13 horas · Según Oppenheimer, se prevé que esta financiación extienda la liquidez financiera de la empresa hasta mediados de 2027, como indicaron recientemente los directivos de Kymera.
Há 13 horas · REDWOOD CITY, Calif., Sept. 27, 2024 (GLOBE NEWSWIRE) -- AmMax Bio, Inc., a private clinical-stage biopharmaceutical company developing innovative therapeutics in oncology, today announced that it ...
Há 13 horas · On Friday, Oppenheimer has increased the price target for shares of Kymera Therapeutics (NASDAQ:KYMR) to $56, up from the previous $52, while maintaining an Outperform rating on the stock. The adjustment follows a recent financing round and reflects the firm's positive view of Kymera's potential in the pharmaceutical industry.
